Switching from messenger RNAs to noncoding RNAs, METTL3 is a novel colorectal cancer diagnosis and treatment target

Figure 4 Expression and function analysis of METTL3. A: Pan-cancer analysis of METTL3; B: Expression of METTL3 in colon adenocarcinoma (COAD); C: METTL3 expression across COAD stages; D: Prognosis of METTL3 in COAD; E: Integration of the top 150 METTL3 target genes; F: Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis of METTL3 targets; G: Drug-protein interaction analysis of Patupilone, YM-155, KIN001-266, and METTL3 in prostate adenocarcinoma. TCGA: The Cancer Genome Atlas; TPM: Transcripts per million; BLCA: Bladder urothelial carcinoma; BRCA: Breast invasive carcinoma; CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL: Cholangiocarcinoma; COAD: Colon adenocarcinoma; ESCA: Esophageal carcinoma; GBM: Glioblastoma multiforme; HNSC: Head and neck squamous cell carcinoma; KICH: Kidney chromophobe; KIRC: Kidney renal clear cell carcinoma; KIRP: Kidney renal papillary cell carcinoma; LIHC: Liver hepatocellular carcinoma; LUAD: Lung adenocarcinoma; LUSC: Lung squamous cell carcinoma; PAAD: Pancreatic adenocarcinoma; PRAD: Prostate adenocarcinoma; PCPG: Pheochromocytoma and paraganglioma; READ: Rectum adenocarcinoma; SARC: Sarcoma; SKCM: Skin cutaneous melanoma; STAD: Stomach adenocarcinoma; UCEC: Uterine corpus endometrial carcinoma; KEGG: Kyoto Encyclopedia of Genes and Genomes.